CNBC’s Jim Cramer delivered an optimistic song on Monday, predicting that once the United States reaches herd immunity to Covid-19, resuming play will surge again.
“If the combination of vaccines and infectious diseases reaches some sort of national pseudo-herd immunity, or even peaks in new cases, a second resumption of travel, leisure, retail, industry and energy strains. It could be something like that, “said the host of” Mad Money. “
“Once they start overcoming this new outbreak, they’ll be a place to invest,” Kramer said, but he didn’t offer stock recommendations.
Kramer acknowledged Dr. Scott Gottlieb for facilitating the purchase of shares on Monday. Using the UK as an indicator, Pfizer’s board member and former US Food and Drug Director told CNBC that Delta transmissions in the US are expected to peak within a month.
Comments made Kramer more positive about his health outlook.
“If you’re worried about nightmare scenarios when Covid burns out, you’ll want to own exactly the kind of stock you’re selling, which refuses to just stop this market. That’s why, “said Kramer.
Kramer is bullish on resuming play, but the market still faces many threats. This includes an increase in Covid cases in the United States caused by highly contagious delta variants and ongoing inflation. Kramer also included infrastructure negotiations in Washington, concerns about debt caps, and geopolitical issues with China as other major risks in the “nightmare scenario.”
Question to Kramer?
Call Kramer: 1-800-743-CNBC
Do you have any questions, comments or suggestions regarding the “Mad Money” website? firstname.lastname@example.org
Disclosure: Scott Gottlieb is a CNBC contributor and member of the board of directors of Pfizer, genetic testing startup Tempus, healthcare technology company Aetion Inc., and biotechnology company Illumina. He is also Co-Chair of Norwegian Cruise Line Holdings and Royal Caribbean’s “Healthy Sail Panel”.
Jim Cramer sees “second reopening” deal on recovery stocks
Source link Jim Cramer sees “second reopening” deal on recovery stocks